HomeCompareALPN vs STAG

ALPN vs STAG: Dividend Comparison 2026

ALPN yields 3.08% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALPN wins by $6.0K in total portfolio value
10 years
ALPN
ALPN
● Live price
3.08%
Share price
$64.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.4K
Annual income
$375.35
Full ALPN calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — ALPN vs STAG

📍 ALPN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALPNSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALPN + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALPN pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALPN
Annual income on $10K today (after 15% tax)
$261.66/yr
After 10yr DRIP, annual income (after tax)
$319.05/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, STAG beats the other by $74.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALPN + STAG for your $10,000?

ALPN: 50%STAG: 50%
100% STAG50/50100% ALPN
Portfolio after 10yr
$21.3K
Annual income
$419.02/yr
Blended yield
1.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALPN right now

ALPN
Analyst Ratings
9
Buy
6
Hold
Consensus: Buy
Price Target
$55.00
-15.3% upside vs current
Range: $44.00 — $65.00
Altman Z
65.0
Piotroski
3/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALPN buys
0
STAG buys
0
No recent congressional trades found for ALPN or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALPNSTAG
Forward yield3.08%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$24.4K$18.3K
Annual income after 10y$375.35$462.70
Total dividends collected$3.4K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$55.00$45.00

Year-by-year: ALPN vs STAG ($10,000, DRIP)

YearALPN PortfolioALPN Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$11,008$307.83$10,665$345.38+$343.00ALPN
2$12,095$316.69$11,365$358.01+$730.00ALPN
3$13,267$325.21$12,099$370.76+$1.2KALPN
4$14,529$333.38$12,870$383.63+$1.7KALPN
5$15,887$341.21$13,678$396.60+$2.2KALPN
6$17,348$348.70$14,526$409.67+$2.8KALPN
7$18,918$355.85$15,413$422.82+$3.5KALPN
8$20,605$362.67$16,343$436.05+$4.3KALPN
9$22,417$369.17$17,315$449.35+$5.1KALPN
10$24,361$375.35$18,332$462.70+$6.0KALPN

ALPN vs STAG: Complete Analysis 2026

ALPNStock

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Full ALPN Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this ALPN vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALPN vs SCHDALPN vs JEPIALPN vs OALPN vs KOALPN vs MAINALPN vs PLDALPN vs EQRALPN vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.